A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Ledipasvir/Sofosbuvir in Subjects With Genotype 1, 4, 5 and 6 Chronic HCV Infection Who Are on Dialysis for End Stage Renal Disease
Phase of Trial: Phase II
Latest Information Update: 05 Aug 2017
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms LDV/SOF ESRD
- Sponsors Gilead Sciences
- 01 Jul 2017 Status changed from not yet recruiting to recruiting.
- 12 Jun 2017 Planned End Date changed from 1 Oct 2018 to 1 Dec 2018.
- 12 Jun 2017 Planned primary completion date changed from 1 Jul 2018 to 1 Sep 2018.